Patents by Inventor Young Ki Paik

Young Ki Paik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10656154
    Abstract: The present application relates to a kit for diagnosing pancreatic cancer, a method for providing information for diagnosing pancreatic cancer using the kit, and a method for diagnosing pancreatic cancer using same, wherein the kit includes an antibody specifically binding to complement factor B protein and an antibody specifically binding to carbohydrate antigen 19-9 protein. According to the present application, it is possible to provide a marker for diagnosing pancreatic cancer having enhanced sensitivity and specificity.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: May 19, 2020
    Assignee: JW HOLDINGS CORPORATION
    Inventors: Young Ki Paik, Min Jung Lee
  • Publication number: 20170153239
    Abstract: The present application relates to a kit for diagnosing pancreatic cancer, a method for providing information for diagnosing pancreatic cancer using the kit, and a method for diagnosing pancreatic cancer using same, wherein the kit includes an antibody specifically binding to complement factor B protein and an antibody specifically binding to carbohydrate antigen 19-9 protein. According to the present application, it is possible to provide a marker for diagnosing pancreatic cancer having enhanced sensitivity and specificity.
    Type: Application
    Filed: November 10, 2016
    Publication date: June 1, 2017
    Inventors: Young Ki PAIK, Min Jung Lee
  • Patent number: 9116152
    Abstract: The present invention relates to monoclonal antibodies which specifically recognize human liver-carboxylesterase 1, hybridoma cell lines which produce monoclonal antibodies, and uses thereof. The invention can be used for the objective analysis of the expression amount of human liver-carboxylesterase 1 in tissues and blood, and the like, by being specifically bound to the human liver-carboxylesterase 1. Therefore, liver cancer can be conveniently and quickly diagnosed from urine or blood.
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: August 25, 2015
    Assignee: Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Young Ki Paik, Keun Na
  • Publication number: 20140154699
    Abstract: The present invention relates to monoclonal antibodies which specifically recognize human liver-carboxylesterase 1, hybridoma cell lines which produce monoclonal antibodies, and uses thereof. The invention can be used for the objective analysis of the expression amount of human liver-carboxylesterase 1 in tissues and blood, and the like, by being specifically bound to the human liver-carboxylesterase 1. Therefore, liver cancer can be conveniently and quickly diagnosed from urine or blood.
    Type: Application
    Filed: April 17, 2012
    Publication date: June 5, 2014
    Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Young Ki Paik, Keun Na
  • Patent number: 8198038
    Abstract: The present invention relates to a plasma biomarker for diagnosing hepatocellular carcinoma (HCC), in particular to the discovery of a protein in plasma using 2-D fluorescence differential gel electrophoresis (2-D DIGE), immunoprecipitation and Nano-liquid chromatography mass spectrometry (Nano-LC-MS/MS) system that was unknown on the basis of conventional techniques. By demonstrating the presence of liver carboxylesterase 1 (hCE1) in human plasma and confirming that its secretion level is higher in patients with HCC than in healthy volunteers, this invention may be used as a screening method to diagnose HCC at an early stage.
    Type: Grant
    Filed: October 1, 2008
    Date of Patent: June 12, 2012
    Assignee: Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Young-Ki Paik, Keun Na
  • Patent number: 7951839
    Abstract: The present invention related to a determination of a stereochemistry, a synthesis and dauer effect of 6R-(3,6-dideoxy-L-arabino-hexopyranosyloxy) heptanoic acid as a pheromone isolated from the Caenorhabditis elegance related to suppression of aging and stress. It becomes possible to develop medical substances using the pheromone relating to aging, stress, metabolism, signal transfer system in vivo, and anticancer, obesity and a suppressing agent for aging and stress.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: May 31, 2011
    Assignee: KDR Biotech. Co. Ltd.
    Inventors: Mankil Jung, Young Ki Paik
  • Publication number: 20110097738
    Abstract: The present invention relates to a plasma biomarker for diagnosing hepatocellular carcinoma (HCC), in particular to the discovery of a protein in plasma using 2-D fluorescence differential gel electrophoresis (2-D DIGE), immunoprecipitation and Nano-liquid chromatography mass spectrometry (Nano-LC-MS/MS) system that was unknown on the basis of conventional techniques. By demonstrating the presence of liver carboxylesterase 1 (hCE1) in human plasma and confirming that its secretion level is higher in patients with HCC than in healthy volunteers, this invention may be used as a screening method to diagnose HCC at an early stage.
    Type: Application
    Filed: October 1, 2008
    Publication date: April 28, 2011
    Inventors: Young-Ki Paik, Keun Na
  • Publication number: 20090221829
    Abstract: The present invention relates to 3,4-dihydroisoquinolinium salt derivatives. More specifically, the present invention relates to 3,4-dihydroisoquinolinium salt derivatives of the following chemical formula (I).
    Type: Application
    Filed: June 1, 2006
    Publication date: September 3, 2009
    Inventors: Jungho Kim, Sangphil Lee, Junyoung Choi, Young-Ki Paik, Yousuk Lee, Hyungmin Joo
  • Patent number: 7576225
    Abstract: The present invention relates to a determination of a stereochemistry, a synthesis and dauer effect of 6R-(3,6-dideoxy-L-arabino-hexopyranosyloxy) heptanoic acid as a pheromone isolated from the Caenorhabditis elegance related to suppress of aging and stress. It becomes possible to develop medical substances using the pheromone relating to aging, stress, metabolism, signal transfer system in vivo, and anti-cancer, obesity and a suppressing agent for aging and stress.
    Type: Grant
    Filed: November 15, 2004
    Date of Patent: August 18, 2009
    Assignee: KDR Biotech. Co. Ltd.
    Inventors: Mankil Jung, Young Ki Paik
  • Publication number: 20080188646
    Abstract: The present invention relates to a determination of a stereochemistry, a synthesis and dauer effect of 6R-(3,6-dideoxy-L-arabino-hexopyranosyloxy)heptanoic acid as a pheromone isolated from the Caenorhabditis elegance related to suppress of aging and stress. It becomes possible to develop medical substances using the pheromone relating to aging, stress, metabolism, signal transfer system in vivo, and anti-cancer, obesity and a suppressing agent for aging and stress.
    Type: Application
    Filed: October 30, 2007
    Publication date: August 7, 2008
    Applicant: KDR Biotech. Co. Ltd.
    Inventors: Mankil Jung, Young Ki Paik
  • Patent number: 7119213
    Abstract: The present invention discloses a method for effectively isolating and purifying a physiological active dauer pheromone compound having the following structural formula I related to aging and stress of C. elegans, and determination of the structure of such material. First, ethanol extract is prepared by completely concentrating a liquid medium with ethanol after culturing C. elegans on a S. basal liquid medium, and then this ethanol fraction is further extracted with ethyl acetate. Then, impurities are removed from ethyl acetate extract by a silica-gel adsorption chromatography and a pheromone extract is isolated and purified by amine column chromatographic procedures using various solvents as eluent. Finally, a pheromone compound having structural formula I is completely isolated and characterized by size-exclusion HPLC.
    Type: Grant
    Filed: October 7, 2003
    Date of Patent: October 10, 2006
    Inventors: Young Ki Paik, Pan Young Jeong
  • Publication number: 20040029910
    Abstract: The present invention relates to protoberberine derivatives which inhibit the activity of mitogen-activated protein kinase. More specifically, the present invention is directed to protoberberine derivatives which inhibit the activity of Wis1 and Spc1 kinase in intracellular signal transduction cascade wherein mitogen-activated protein kinase (MAPK) is involved.
    Type: Application
    Filed: July 28, 2003
    Publication date: February 12, 2004
    Inventors: Ki-Won Song, Mi-Ri Jwa, Myoung-Jin Jang, Young-Ki Paik, Jun-Ho Kim
  • Patent number: 6255317
    Abstract: The present invention provides a cholesterol biosynthesis inhibitor which specifically inhibits the sterol 14-reductase which is involved in the distal pathway of cholesterol biosynthesis, a compound of formula (1) below and the use of an extract or the compound of formula (1) for treating hypercholesterolaemia or hyperlipidaemia. The inhibitor comprises an extract obtained by extracting Corydalis Turtschaninowii Besser with a solvent, or an organic layers obtained by partitioning an extract from Corydalis Turtschaninowii Besser with an organic solvent. The extract contains 7,8,13,13&agr;-tetrahydrocoridaline or its derivative, as the active ingredients, which specifically inhibits the enzyme which is involved in the distal pathway of the cholesterol biosynthesis.
    Type: Grant
    Filed: January 20, 1999
    Date of Patent: July 3, 2001
    Assignee: Hanwha Chemical Corporation
    Inventors: Jung Ho Kim, Tae Neung Jhong, Young Ki Paik, Joon Seo Park, Eui Deok Kim, You Suk Lee, Seung Un Kim
  • Patent number: 6239139
    Abstract: The present invention provides a cholesterol biosynthesis inhibitor which specifically inhibits the sterol 14-reductase which is involved in the distal pathway of cholesterol biosynthesis, a compound of formula (1) below and the use of an extract or the compound of formula (1) for treating hypercholesterolaemia or hyperlipidaemia. The inhibitor comprises an extract obtained by extracting Corydalis Turtschaninowii Besser with a solvent, or an organic layers obtained by partitioning an extract from Corydalis Turtschaninowii Besser with an organic solvent. The extract contains 7,8,13,13&agr;-tetrahydrocoridaline or its derivative, as the active ingredients, which specifically inhibits the enzyme which is involved in the distal pathway of the cholesterol biosynthesis.
    Type: Grant
    Filed: January 20, 1999
    Date of Patent: May 29, 2001
    Assignee: Hanwha Chemical Corporation
    Inventors: Jung Ho Kim, Tae Neung Jhong, Young Ki Paik, Joon Seo Park, Eui Deok Kim, You Suk Lee, Seung Un Kim
  • Patent number: 6030979
    Abstract: The present invention provides a pharmaceutical composition comprising 5,6-dihydrodibenzo[a,g]quinolizinium derivative and the salts thereof of formula (I) which specifically inhibits the sterol 14-reductase which is involved in the distal pathway of cholesterol biosynthesis, and the use of the compound of formula (I) for treating hypercholesterolaemia or hyperlipidaemia.
    Type: Grant
    Filed: January 22, 1999
    Date of Patent: February 29, 2000
    Assignee: Hanwha Corporation
    Inventors: Jung Ho Kim, Tae Neung Jhong, Young Ki Paik, Joon Seo Park, Eui Deok Kim, You Suk Lee, Seung Un Kim
  • Patent number: 6030978
    Abstract: The antifungal formulation comprising the novel compounds of the following chemical formulae (I) and (II) exhibit in vitro antifungal activity against fungi including cutaneous filamentous fungus, such as Epidermophyton, Microsporum, Trichophyton, Sporothrix schenckii, Aspergillus or Candida. The formulation of the present invention exhibit in vitro antifungal activity at the concentration of 1-100 .mu.g/ml. ##STR1## wherein R.sup.1, R.sup.2, and R.sup.4 may be the same or different, and represent C.sub.1 -C.sub.5 alkoxy, R.sup.3 represents hydrogen or C.sub.1 -C.sub.10 alkyl, A.sup.- represents inorganic acid ion, organic acid ion or halide, R.sup.5 represents hydrogen, pyridylmethyl, substituted pyridylmethyl or a group having the following chemical formula(XI) ##STR2## wherein Z.sup.1, Z.sup.2, Z.sup.3, Z.sup.4 and Z.sup.5 may be the same or different and represent hydrogen, halogen, C.sub.1 -C.sub.5 alkyl, trifluoromethyl, phenyl, substituted phenyl, nitro, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.
    Type: Grant
    Filed: December 10, 1998
    Date of Patent: February 29, 2000
    Assignee: Hanwha Corporation
    Inventors: Jung Ho Kim, Tae Neung Jhong, Young Ki Paik, Joon Seo Park, Eui Deok Kim, You Suk Lee, Seung Un Kim
  • Patent number: 6028197
    Abstract: The present invention provides a 5,6-dihydrodibenzo[a,g]quinolizinium derivative and the salts thereof of formula (I) which specifically inhibits the sterol 14-reductase which is involved in the distal pathway of cholesterol biosynthesis, and the use of the compound of formula (I) for treating hypercholesterolaemia or hyperlipidaemia. ##STR1## wherein, R.sup.1 and R.sup.2 which may be the same or different from each other, represent a hydroxy group or an alkoxy group having 1 to 4 carbons or R.sup.1 and R.sup.2 together represent a methylenedioxy group;R.sup.3 represents a hydroxy group or an alkoxy group having 1 to 4 carbons;R.sup.
    Type: Grant
    Filed: January 22, 1999
    Date of Patent: February 22, 2000
    Assignee: Hanwha Corporation
    Inventors: Jung Ho Kim, Tae Neung Jhong, Young Ki Paik, Joon Seo Park, Eui Deok Kim, You Suk Lee, Seung Un Kim
  • Patent number: 6008356
    Abstract: The novel compounds of the following chemical formulae (I) and (II) exhibit in vitro antifungal activity against fungi including cutaneous filamentous fungus, such as Epidermophyton, Microsporum, Trichophyton, Sporothrix schenckii, Aspergillus or Candida. The compounds of the present invention exhibit in vitro antifungal activity at the concentration of 1-100 .mu.g/ml. ##STR1## wherein R.sup.1, R.sup.2, and R.sup.4 may be the same or different, and represent C.sub.1 -C.sub.5 alkoxy, R.sup.3 represents hydrogen or C.sub.1 -C.sub.10 alkyl, A.sup.- represents inorganic acid ion, organic acid ion or halide, R.sup.5 represents hydrogen, pyridylmethyl, substituted pyridylmethyl or a group having the following chemical formula(XI) ##STR2## wherein Z.sup.1, Z.sup.2, Z.sup.3, Z.sup.4 and Z.sup.5 may be the same or different and represent hydrogen, halogen, C.sub.1 -C.sub.5 alkyl, trifluoromethyl, phenyl, substituted phenyl, nitro, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkylamino, acetylamino, C.sub.1 -C.sub.
    Type: Grant
    Filed: December 10, 1998
    Date of Patent: December 28, 1999
    Assignee: Hanwha Corporation
    Inventors: Jung Ho Kim, Tae Neung Jhong, Young Ki Paik, Joon Seo Park, Eui Deok Kim, You Suk Lee, Seung Un Kim
  • Patent number: RE46572
    Abstract: The present invention relates to a plasma biomarker for diagnosing hepatocellular carcinoma (HCC), in particular to the discovery of a protein in plasma using 2-D fluorescence differential gel electrophoresis (2-D DIGE), immunoprecipitation and Nano-liquid chromatography mass spectrometry (Nano-LC-MS/MS) system that was unknown on the basis of conventional techniques. By demonstrating the presence of liver carboxylesterase 1 (hCE1) in human plasma and confirming that its secretion level is higher in patients with HCC than in healthy volunteers, this invention may be used as a screening method to diagnose HCC at an early stage.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: October 17, 2017
    Assignee: Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Young-Ki Paik, Keun Na